Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by rgonlyfactsplson Oct 05, 2017 12:45pm
148 Views
Post# 26781330

RE:RE:RE:RE:RE:Short's....House #1 Trading and our regulators

RE:RE:RE:RE:RE:Short's....House #1 Trading and our regulatorsSuggest speaking up. I don't watch the trading but have addressed other matters (non PLI). Here is a contact at OSC... From: OSC_General_Inquiries/StratOps/OSC [mailto:OSC_General_Inquiries/StratOps/OSC] On Behalf Of inquiries@osc.gov.on.ca To: Robert Subject: Re: Dear Mr........: Thank you for your follow up email to the Ontario Securities Commission (OSC) concerning disclosure made by ........ I have forwarded the information you provided to the Corporate Finance branch of the OSC for further review. Their review of this matter will focus on any potential violation of Ontario securities law, and in particular disclosure related concerns. Please note that regulatory reviews, and any subsequent investigation, are conducted privately. Any issues that staff may identify will be addressed with the issuer directly. Sincerely, Conor Breslin Lead Inquiries Officer Ontario Securities Commission inquiries@osc.gov.on.ca 416-593-8314 1-877-785-1555 The information in this e-mail should be taken as a guide. The content is not intended to provide investment, financial accounting, legal, tax or other professional advice and should not be relied upon or regarded as a substitute for such advice. We recommend that you seek advice from a qualified professional adviser before acting on the information or content appearing in this e-mail or any information or content on a web site to which a link has been provided.
Bullboard Posts